ST Pharm and Quantoom Biosciences Expand Collaboration to Advance RNA Manufacturing
Global API CDMO, ST Pharm, and mRNA bioprocessing provider, Quantoom Biosciences, have announced a supply agreement for an extended collaboration on Quantoom's proprietary SmartCap technology. The companies claim the partnership will enhance RNA manufacturing processes by focusing on innovative solutions for the development of RNA-based therapeutics, and that the agreement marks a significant step in advancing production capabilities to improve efficiency and scalability in the manufacturing of RNA molecules.
ST Pharm, a leading technology-driven RNA CDMO, and Quantoom Biosciences (also referred as “Quantoom”), a specialized RNA technology platform developer, today announced an extended collaboration to accelerate the development and manufacturing of RNA-based vaccines and therapeutics. This collaboration brings together complementary expertise to enhance the global supply of critical RNA manufacturing technologies, with a first supply agreement of ST Pharm’s proprietary 5’-capping reagent, SmartCap®.
By combining their respective strengths and expertise, ST Pharm and Quantoom aim to expand their global reach and provide comprehensive solutions to the RNA manufacturing market. This partnership will enable both companies to leverage their technologies more effectively, accelerating the development and production of innovative RNA-based therapies.
This initial collaboration paves the road to an extended partnership in which ST Pharm’s proprietary and advanced IVT-based mRNA-LNP platform, including novel capping and formulation reagents, will be made available with Quantoom’s Ntensify™ and Ncapsulate™ mRNA production platform, with the aim to create a more robust and flexible RNA manufacturing ecosystem.
As a CDMO, ST Pharm will gain valuable insights into Quantoom’s NtensifyTM mRNA production processes, while Quantoom will benefit from the expanded capabilities enabled by ST Pharm’s unique technologies which will result in unprecedented levels of manufacturing flexibility for its customers.
“We are excited to partner with Quantoom Biosciences to advance the field of RNA therapeutics,” said Mooje Sung, CEO at ST Pharm. “This collaboration represents a significant step forward in our mission to provide cutting-edge and competitive RNA technologies to the global market. By combining our strengths, we can accelerate the development of life-changing RNA-based therapies.”
José Castillo, CEO at Quantoom Biosciences commented: “This collaboration with ST Pharm marks a significant step forward for Quantoom and our NtensifyTM platform. By securing access to ST Pharm’s unique technologies, we are empowering our clients with unparalleled flexibility and control over their mRNA production processes. This partnership is a testament to our commitment to delivering cutting-edge solutions that drive innovation in the mRNA therapeutics space.”
For more, please find the original story source here.
